Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies - PubMed (original) (raw)
Randomized Controlled Trial
. 2007 Mar;46(3):496-507.
doi: 10.1093/rheumatology/kel296. Epub 2006 Aug 27.
Affiliations
- PMID: 16936327
- DOI: 10.1093/rheumatology/kel296
Randomized Controlled Trial
Efficacy and safety of etoricoxib 30 mg and celecoxib 200 mg in the treatment of osteoarthritis in two identically designed, randomized, placebo-controlled, non-inferiority studies
C O Bingham 3rd et al. Rheumatology (Oxford). 2007 Mar.
Abstract
Objective: To compare the efficacy of etoricoxib 30 mg with the generally maximum recommended dose of celecoxib, 200 mg, in the treatment of osteoarthritis (OA) in two identically designed studies.
Methods: Two multi-centre, 26-week, double-blind, placebo-controlled, non-inferiority studies were conducted, enrolling patients who were prior non-steroidal anti-inflammatory drug (NSAID) or acetaminophen users. There were 599 patients in study 1 and 608 patients in study 2 randomized 4:4:1:1 to etoricoxib 30 mg qd, celecoxib 200 mg qd or one of two placebo groups for 12 weeks. After 12 weeks, placebo patients were evenly distributed to etoricoxib or celecoxib based on their initial enrollment randomization schedule. The primary hypothesis was that etoricoxib 30 mg would be at least as effective as celecoxib 200 mg for the time-weighted average change from baseline over 12 weeks for Western Ontario and McMaster (WOMAC) Pain Subscale, WOMAC Physical Function Subscale and Patient Global Assessment of Disease Status. Active treatments were also assessed over the full 26 weeks. Adverse experiences were collected for safety assessment.
Results: In both studies, etoricoxib was non-inferior to celecoxib for all three efficacy outcomes over 12 and 26 weeks; both were superior to placebo (P < 0.001) for all three outcomes in each study over 12 weeks. The safety and tolerability of etoricoxib 30 mg qd and celecoxib 200 mg qd were similar over 12 and 26 weeks.
Conclusions: Etoricoxib 30 mg qd was at least as effective as celecoxib 200 mg qd and had similar safety in the treatment of knee and hip OA; both were superior to placebo. ClinicalTrials.gov Identifiers: NCT00092768; NCT00092791.
Comment in
- COX-2 inhibitor.
Gøtzsche PC, Bjarnason NH. Gøtzsche PC, et al. Rheumatology (Oxford). 2007 Oct;46(10):1623-4; author reply 1624-5. doi: 10.1093/rheumatology/kem216. Epub 2007 Aug 27. Rheumatology (Oxford). 2007. PMID: 17726033 No abstract available.
Similar articles
- Etoricoxib in the treatment of Korean patients with osteoarthritis in a double-blind, randomized controlled trial.
Yoo MC, Yoo WH, Kang SB, Park YW, Kim SS, Moon KH, Song YW, Min BW, Cho YJ, Moon SH, Bin SI, Baek HJ, Shim SC, Lee SW, Yoo DH, Mehta A, Skuban A, Cukrow DM, Vandormael K, Yan L. Yoo MC, et al. Curr Med Res Opin. 2014 Dec;30(12):2399-408. doi: 10.1185/03007995.2014.955169. Epub 2014 Sep 3. Curr Med Res Opin. 2014. PMID: 25133963 Clinical Trial. - Predictors of response to cyclo-oxygenase-2 inhibitors in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib, and placebo.
Bingham CO 3rd, Smugar SS, Wang H, Peloso PM, Gammaitoni A. Bingham CO 3rd, et al. Pain Med. 2011 Mar;12(3):352-61. doi: 10.1111/j.1526-4637.2011.01060.x. Epub 2011 Feb 18. Pain Med. 2011. PMID: 21332932 Clinical Trial. - Early response to COX-2 inhibitors as a predictor of overall response in osteoarthritis: pooled results from two identical trials comparing etoricoxib, celecoxib and placebo.
Bingham CO 3rd, Smugar SS, Wang H, Tershakovec AM. Bingham CO 3rd, et al. Rheumatology (Oxford). 2009 Sep;48(9):1122-7. doi: 10.1093/rheumatology/kep184. Epub 2009 Jul 9. Rheumatology (Oxford). 2009. PMID: 19589894 - Tolerability of selective cyclooxygenase 2 inhibitors used for the treatment of rheumatological manifestations of inflammatory bowel disease.
Miao XP, Li JS, Ouyang Q, Hu RW, Zhang Y, Li HY. Miao XP, et al. Cochrane Database Syst Rev. 2014 Oct 23;2014(10):CD007744. doi: 10.1002/14651858.CD007744.pub2. Cochrane Database Syst Rev. 2014. PMID: 25340915 Free PMC article. Review. - Clinical use and pharmacological properties of selective COX-2 inhibitors.
Shi S, Klotz U. Shi S, et al. Eur J Clin Pharmacol. 2008 Mar;64(3):233-52. doi: 10.1007/s00228-007-0400-7. Epub 2007 Nov 13. Eur J Clin Pharmacol. 2008. PMID: 17999057 Review.
Cited by
- Clinical pharmacokinetic and pharmacodynamic profile of etoricoxib.
Takemoto JK, Reynolds JK, Remsberg CM, Vega-Villa KR, Davies NM. Takemoto JK, et al. Clin Pharmacokinet. 2008;47(11):703-20. doi: 10.2165/00003088-200847110-00002. Clin Pharmacokinet. 2008. PMID: 18840026 Review. - Systemic inflammatory response syndrome in Sepsis-3: a retrospective study.
Zhang W, Zheng Y, Feng X, Chen M, Kang Y. Zhang W, et al. BMC Infect Dis. 2019 Feb 11;19(1):139. doi: 10.1186/s12879-019-3790-0. BMC Infect Dis. 2019. PMID: 30744579 Free PMC article. - Using a discrete choice experiment to elicit patients' preferences and willingness-to-pay for knee osteoarthritis treatments in Thailand.
Luksameesate P, Tanavalee A, Ngorsuraches S, Taychakhoonavudh S. Luksameesate P, et al. Sci Rep. 2023 Jul 27;13(1):12154. doi: 10.1038/s41598-023-39264-6. Sci Rep. 2023. PMID: 37500677 Free PMC article. - Etoricoxib improves osteoarthritis pain relief, joint function, and quality of life in the extreme elderly.
Huang WN, Tso TK. Huang WN, et al. Bosn J Basic Med Sci. 2018 Feb 20;18(1):87-94. doi: 10.17305/bjbms.2017.2214. Bosn J Basic Med Sci. 2018. PMID: 28954205 Free PMC article. Clinical Trial. - Defining acute flares in knee osteoarthritis: a systematic review.
Parry EL, Thomas MJ, Peat G. Parry EL, et al. BMJ Open. 2018 Jul 19;8(7):e019804. doi: 10.1136/bmjopen-2017-019804. BMJ Open. 2018. PMID: 30030311 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical